A functional glycoproteomics approach identifies CD13 as a novel E-selectin ligand in breast cancer

M A Carrascal, M Silva, J A Ferreira, R Azevedo, D Ferreira, A M N Silva, D Ligeiro, L L Santos, R Sackstein, P A Videira

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


BACKGROUND: The glycan moieties sialyl-Lewis-X and/or -A (sLeX/A) are the primary ligands for E-selectin, regulating subsequent tumor cell extravasation into distant organs. However, the nature of the glycoprotein scaffolds displaying these glycans in breast cancer remains unclear and constitutes the focus of the present investigation.

METHODS: We isolated glycoproteins that bind E-selectin from the CF1_T breast cancer cell line, derived from a patient with ductal carcinoma. Proteins were identified using bottom-up proteomics approach by nanoLC-orbitrap LTQ-MS/MS. Data were curated using bioinformatics tools to highlight clinically relevant glycoproteins, which were validated by flow cytometry, Western blot, immunohistochemistry and in-situ proximity ligation assays in clinical samples.

RESULTS: We observed that the CF1_T cell line expressed sLeX, but not sLeA and the E-selectin reactivity was mainly on N-glycans. MS and bioinformatics analysis of the targeted glycoproteins, when narrowed down to the most clinically relevant species in breast cancer, identified as key E-selectin ligands, CD44 glycoprotein (HCELL) and also CD13. Additionally, the co-expression of sLeX-CD44 and sLeX-CD13 was confirmed in clinical breast cancer tissue samples.

CONCLUSIONS: Both CD44 and CD13 glycoforms display sLeX in breast cancer and bind E-selectin, suggesting a key role in metastasis development. Such observations provide a novel molecular rationale for developing targeted therapeutics.

GENERAL SIGNIFICANCE: While HCELL expression in breast cancer has been previously reported, this is the first study indicating that CD13 functions as an E-selectin ligand in breast cancer. This observation supports previous associations of CD13 with metastasis and draws attention to this glycoprotein as an anti-cancer target.

Original languageEnglish
Pages (from-to)2069-2080
JournalBiochimica Et Biophysica Acta
Issue number9
Early online date16 May 2018
Publication statusPublished - Sept 2018


  • Breast cancer
  • CD13
  • CD44
  • E-selectin ligand
  • sLeX


Dive into the research topics of 'A functional glycoproteomics approach identifies CD13 as a novel E-selectin ligand in breast cancer'. Together they form a unique fingerprint.

Cite this